文献速递物质与行为成瘾精神分裂症与精神病性障碍儿童青少年精神

大麻重新列管:医学还是政治?

Rescheduling Cannabis-Medicine or Politics?
PubMed 文献 · JAMA Psychiatry · 2025-01-01

本文批判美国卫生与公众服务部(HHS)2023年建议将大麻从附表I降至附表III的理由。作者指出HHS未充分处理大麻使用障碍高患病率、青少年风险及精神病关联等危害,且仅少数医生推荐大麻、FDA未批准其作为药物,认为HHS依赖有问题的对照药选择并低估不良事件。

要点

  • HHS建议将大麻从附表I降至附表III,偏离长期联邦决定。
  • HHS未充分处理大麻使用障碍高患病率、青少年风险及精神病关联。
  • FDA未批准大麻为药物,因高质量试验、标准化制剂等证据不足。

核心结论

  • HHS重新分类大麻的理由依赖有问题的对照药选择,低估大麻使用者特有不良事件,并缺乏说服力地声称大麻在医疗实践中被广泛接受且有科学证据支持。

研究设计与样本

  • 本文为对HHS建议的批判性评论,基于HHS致DEA管理员信函及相关法律标准进行分析。

主要发现

  • HHS未充分处理大麻使用的不良效应,包括使用者中大麻使用障碍高患病率、青少年消费风险及越来越多的证据 linking cannabis to psychosis。
  • HHS声称大麻被广泛接受为合法药物,但仅一小部分患者照护医生推荐其缓解症状,且实践常偏离医疗规范。
  • FDA未批准大麻为药物,因高质量临床试验数据、标准化大麻制剂、纯度、给药途径、剂量指南及具体使用频率等关键领域证据不足。

关键数值与推荐

  • HHS部长(顾问)与US司法部长(决策者)在决定是否重新列管受控物质时须考虑8个因素和5部分测试。
  • CSA分类标准包括药物当前是否具有公认医疗用途、是否具有滥用潜力及在医疗监督下使用是否安全。

临床怎么用

  • 临床医生应知晓大麻使用障碍高患病率、青少年风险及与精神病的关联,并注意FDA未批准大麻为药物。

局限性

  • 本文为评论性文章,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In 2023, the US Department of Health and Human Services (HHS) issued a letter to the administrator of the Drug Enforcement Administration (DEA) recommending rescheduling of cannabis (marijuana) from Schedule I to Schedule III under the Controlled Substances Act (CSA). This recommendation marked a significant departure from previous, consistent, and long-standing federal decisions on cannabis scheduling. OBJECTIVE: To critique the arguments made by HHS for recommending marijuana rescheduling. EVIDENCE: The HHS secretary (advisor) and US attorney general (decision maker) must consider 8 factors and a 5-part test when deciding whether to reschedule a controlled substance. CSA classification criteria include whether a drug has currently accepted medical use, whether it has abuse potential, and whether use is safe under medical supervision. HHS undermined these established legal scheduling criteria by introducing new, untested criteria. FINDINGS: HHS failed to adequately address the adverse effects of cannabis use, including the high prevalence of cannabis use disorder among users, risks associated with youth consumption, growing evidence linking cannabis to psychosis, and other significant concerns. HHS asserted that cannabis is widely accepted as a legitimate form of medicine, despite the reality that only a small fraction of patient-care physicians recommend it for symptom relief, in practices that often diverge from the norms of medical practice. Finally, the US Food and Drug Administration has not approved cannabis as a medicine, as evidence is deficient in several key areas, including data from high-quality clinical trials, standardized cannabis formulations, established purity, defined routes of administration, dosing guidelines, and specific frequencies of use. CONCLUSIONS AND RELEVANCE: The HHS rationale for reclassifying cannabis in myriad forms (edibles, smokables, drinkables, vaping products, suppositories) and potencies relies on a questionable selection of comparator drugs, downplays distinctive adverse events among cannabis users, and claims, unconvincingly, that cannabis has wide acceptance in medical practice supported by scientific evidence.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Madras BK, Larkin PJ. Rescheduling Cannabis-Medicine or Politics? JAMA Psychiatry. 2025. PMID: 40498499. doi:10.1001/jamapsychiatry.2025.1116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。